Acurx Pharmaceuticals Inc - ACXP STOCK NEWS

Acurx Pharmaceuticals, Inc. (ACXP) will be presenting at The 14th Annual LD Micro Invitational on April 8th-9th, 2024. The event will showcase 80 companies with Acurx scheduled to present on April 8th at 2:30 pm ET.

Acurx Pharmaceuticals, Inc. (ACXP) reported positive Phase 2b clinical trial results for ibezapolstat in treating C. difficile infection. The trial demonstrated a high clinical cure rate of 96%, outperforming vancomycin. The company submitted data to the FDA for an End of Phase 2 Meeting and received SME designation from the EMA. Despite positive clinical data, financial results showed a decrease in cash position, increased R&D and G&A expenses, and a net loss for the quarter and year.

Acurx Pharmaceuticals, Inc. (ACXP) to Release Q4 and Full Year 2023 Financial Results on March 18, 2024

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announces FDA EOP2 meeting granted to discuss Phase 3 development plan for ibezapolstat in treating CDI. The Company submitted pre-meeting Briefing Document and received SME designation from EMA for EU Marketing Authorization.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced positive extended clinical cure data for ibezapolstat (IBZ) from the Phase 2b trial in patients with CDI. 100% of IBZ patients experienced no recurrence of infection, and further analyses on bile acid metabolism and pharmacokinetic data are forthcoming. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation. The company is preparing for meetings with regulatory agencies and advancement to international Phase 3 clinical trials.

Acurx Pharmaceuticals, Inc. announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference to discuss the development of small molecule antibiotics for bacterial infections. The conference will take place from January 30th to February 1st at the Ceasars Atlantic City Hotel & Casino. Interested parties can register to attend the presentation on January 31st and February 1st.

Acurx Pharmaceuticals, Inc. (ACXP) has announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company's recently completed Phase 2b clinical trial in patients with CDI. The data showed that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (94%) versus vancomycin which had eradication of fecal C. difficile in 10 of 14 patients (71%). Further analyses will be forthcoming Q1 2024, regarding other endpoints from the Phase 2b trial, including Extended Clinical Cure (ECC) data up to 94 days. Preparation is underway for meetings with FDA, European Medicines Agency and other global regulatory agencies and advancement to international Phase 3 clinical trials. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation. The company also anticipates its price point for ibezapolstat, if approved, could meet or beat other antibiotics recommended for use in treating patients with CDI, thereby providing the whole package of clinical comparability with microbiome health, safety, and cost for patients with this life-threatening disease.

Acurx Pharmaceuticals, Inc. (ACXP) President and CEO David P. Luci to present at 42nd Annual J.P. Morgan Healthcare Conference

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced positive Phase 2b results showing 100% of CDI patients who had Clinical Cure with ibezapolstat also had Sustained Clinical Cure. The company is developing a new class of small molecule antibiotics for bacterial infections. Phase 2a and Phase 2b combined showed 96% Clinical Cure and 100% Sustained Clinical Cure for ibezapolstat. Vancomycin had 100% Clinical Cure and 86% Sustained Clinical Cure. Further analyses will be forthcoming Q1 2024 for other endpoints and comparative effects vs vancomycin on the gut microbiome.